# A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone

> **NCT02288247** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Europe Ltd.** · enrollment: 688 (actual)

## Conditions studied

- Metastatic Castration Resistant Prostate Cancer

## Interventions

- **DRUG:** Enzalutamide
- **DRUG:** Docetaxel
- **DRUG:** Prednisolone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02288247
- **Lead sponsor:** Astellas Pharma Europe Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-01
- **Primary completion:** 2020-04-30
- **Final completion:** 2024-03-15
- **Target enrollment:** 688 (ACTUAL)
- **Last updated:** 2025-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02288247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02288247, "A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02288247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*